Edition:
United Kingdom

Avenue Therapeutics Inc (ATXI.OQ)

ATXI.OQ on NASDAQ Stock Exchange Capital Market

6.18USD
19 Jul 2019
Change (% chg)

$0.19 (+3.17%)
Prev Close
$5.99
Open
$6.00
Day's High
$6.18
Day's Low
$6.00
Volume
2,498
Avg. Vol
14,711
52-wk High
$7.95
52-wk Low
$2.10

Latest Key Developments (Source: Significant Developments)

Avenue Therapeutics Q3 Loss Per Share $0.25
Wednesday, 14 Nov 2018 

Avenue Therapeutics Inc ::AVENUE THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q3 LOSS PER SHARE $0.25.  Full Article

Avenue Therapeutics Reports Q4 Loss Per Share $0.63
Thursday, 1 Mar 2018 

March 1 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q4 LOSS PER SHARE $0.63.  Full Article

Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018.AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018.  Full Article

Avenue Therapeutics reports Q3 loss per share $0.30
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics Inc reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.30.  Full Article

Avenue Therapeutics doses first patient in postoperative pain trial
Wednesday, 27 Sep 2017 

Sept 27 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics announces dosing of first patient in pivotal Phase 3 clinical trial of intravenous tramadol for the management of postoperative pain.Avenue Therapeutics Inc says ‍expect to report topline data in Q2 of 2018​.Avenue Therapeutics Inc - about 405 patients will be enrolled to IV tramadol 50 mg, IV tramadol 25 mg or placebo in a 1:1:1 ratio​.  Full Article